Key Takeaway
Melatonin may not be effective for chronic insomnia in adults but shows promise in children and adolescents, with significant improvements in sleep onset latency and total sleep time in younger populations.
Summary
This systematic review and meta-analysis examined 24 RCTs evaluating melatonin for chronic insomnia, including both non-comorbid and comorbid insomnia across different age groups. The review searched Ovid-MEDLINE, EMBASE, and Cochrane Library through November 2020.
Notably, the analysis found age-dependent effects: melatonin significantly reduced sleep onset latency and improved total sleep time in children and adolescents, but was not significantly effective in adults with non-comorbid chronic insomnia. For comorbid insomnia, melatonin improved sleep onset latency across all age groups, though adult data was limited to a single study.
This study challenges the assumption that melatonin is equally effective across all populations for chronic insomnia, suggesting its primary utility may be in pediatric sleep disorders and circadian-related issues rather than chronic adult insomnia.
Methods
- Systematic review of Ovid-MEDLINE, EMBASE, and Cochrane Library
- 24 randomized controlled trials included (4 with comorbid insomnia)
- Outcomes: sleep onset latency, total sleep time, sleep efficiency, sleep quality, quality of life
- Subgroup analyses performed by age group due to heterogeneity
- Literature search through November 2020
Key Results
- Non-comorbid insomnia in adults: no significant improvement in sleep onset latency, total sleep time, or sleep efficiency
- Non-comorbid insomnia in children/adolescents: significant improvements in sleep onset latency and total sleep time
- Comorbid insomnia: significant improvement in sleep onset latency across all age groups
- Limited adult data for comorbid insomnia (only one study)
Limitations
- Significant heterogeneity across included studies
- Limited number of studies in pediatric populations
- Only one adult study available for comorbid insomnia analysis
- Variable dosing protocols across trials
- Definition of chronic insomnia varied between studies
- No specific dose-response analysis reported